The BRCA1 and BRCA2 proteins are involved in the maintenance of genome stability and germ-line loss-offunction mutations in either BRCA1 or BRCA2 strongly predispose carriers to cancers of the breast and other organs. It has been demonstrated previously that inhibiting elements of the cellular DNA maintenance pathways represents a novel therapeutic approach to treating tumors in these individuals. Here, we show that inhibition of the telomere-associated protein, Tankyrase 1, is also selectively lethal with BRCA deficiency. We also demonstrate that the selectivity caused by inhibition of Tankyrase 1 is associated with an exacerbation of the centrosome amplification phenotype associated with BRCA deficiency. We propose that inhibition of Tankyrase 1 could be therapeutically exploited in BRCAassociated cancers.
Introduction
Germ-line mutations in either BRCA1 or BRCA2 strongly predispose individuals to cancers of the breast and also to malignancies of the ovaries, pancreas and prostate gland. Tumors arising in women carrying a single germ-line mutant BRCA allele exhibit loss of heterozygosity at the BRCA locus, losing the wild-type allele and retaining the mutant copy of the gene, suggesting that BRCA1 and BRCA2 act as tumor suppressors , and references therein). BRCA1-or BRCA2-deficient cells have defects in the repair of DNA double-strand breaks (DSBs) by the conservative, error-free pathway of homologous recombination (HR), leading to cellular sensitivity to specific DNA-damaging agents . This has been previously exploited in the design of novel therapies to treat BRCA-associated cancers, including the demonstration that inhibition of the DNA repair enzyme poly(ADP)-ribose polymerase (PARP1) is particularly selective for BRCA-deficient cells (Bryant et al., 2005; Farmer et al., 2005) . The profound sensitivity of BRCAdeficient cells to PARP inhibition exemplifies the concept of synthetic lethality. Two genes or proteins exhibit a synthetic lethal interaction when loss of either gene is not overtly deleterious but loss of both is lethal (Kaelin, 2005) . In scenarios such as BRCA-associated cancer, where recapitulation of a wild-type tumor suppressor is impractical, synthetic lethality presents an attractive approach to the identification of therapeutic targets (Iorns et al., 2007) . Despite the potential of PARP inhibition in BRCA-associated cancers, it is possible that some patients will either be inherently refractory to this approach or develop drug resistance. Therefore, it is vital to identify additional therapeutic targets for BRCA-associated cancers.
Our previous observations on the efficacy of PARP inhibition led us to an assessment of the other members of the PARP superfamily, which includes at least 17 members divided into three subfamilies based on their enzymatic characteristics (Ame et al., 2004; Kleine et al., 2008) . The first subfamily includes members with PARP activity (PARP1-5), the second includes proteins with mono(ADP)ribosyltransferase activity (PARP6, 8, (10) (11) (12) and the third constitutes catalytically inactive members of the superfamily (PARP9, 13) (Kleine et al., 2008) . In particular, we have focused on one member, Tankyrase 1 (PARP5a). Tankyrase 1 was identified by its ability to bind TRF1, a positive regulator of telomere length (Smith et al., 1998; Seimiya et al., 2004) . Tankyrase 1 binding to TRF1 results in poly(ADP-ribosyl)ation of TRF1 and leads to TRF1 release from the telomeres and its proteolytic degradation (Chang et al., 2003) . Consistent with these observations, overexpression of Tankyrase 1 results in telomere elongation (Seimiya et al., 2004) . The interaction between Tankyrase 1 and TRF1 requires the C-terminal region of Tankyrase 1 (Seimiya et al., 2004) .
This region contains a domain of 24 ankyrin (ANK) repeats, which are organized in five highly conserved subdomains (ARC1-V, or ANK repeat clusters) (Seimiya and Smith, 2002; Seimiya et al., 2004) . Although TRF1 binds to all five ARC subdomains, only the ARCV domain is required for its poly(ADP-ribosyl)ation and release from the telomeres (Seimiya et al., 2004) . In agreement with an involvement of Tankyrase 1 in telomere maintenance, a recent report showed that inhibition of Tankyrase 1 accentuates the ability of a telomerase inhibitor, MST-312 to induce telomere shortening (Seimiya et al., 2005) , indicating that Tankyrase 1 may be a potential therapeutic target (Seimiya, 2006) . Besides its telomere function, Tankyrase 1 has also been localized to the Golgi and to the mitotic spindle poles (Smith and de Lange, 1999; Chi and Lodish, 2000) . A reduction in Tankyrase 1 expression has also been shown to cause cells to accumulate in M phase (Dynek and Smith, 2004) and have abnormal spindle structures , suggesting involvement of Tankyrase 1 in spindle structure and function.
It has previously been demonstrated that targeting DNA repair pathways in BRCA-deficient cells can illuminate synthetic lethal interactions and lead to the development of novel therapeutic approaches . Therefore, we investigated the possibility of synthetic lethal interactions between Tankyrase 1 and BRCA1 or BRCA2. We demonstrate that targeting Tankyrase 1 is selectively lethal in the context of BRCA deficiency.
Results and discussion
To assess the possibility that targeting Tankyrase 1 may have utility in the treatment of tumors associated with loss of BRCA1 or BRCA2 function, we developed a human colon cancer cell line, HCT116, with stable reduction of Tankyrase 1 expression (Figure 1a ). This was achieved by infection with a retroviral vector expressing either a short-hairpin RNA (shRNA) targeting Tankyrase 1 (catalogue no. RHS1764-9688056) or a control nontargeting shRNA (catalogue no. RHS1703; Open Biosystems, Huntsville, AL, USA). Tankyrasesilenced cells (HCT116-Tankyrase 1 shRNA) and control cells (HCT116-Control shRNA) were subsequently transfected with pSUPER shRNA constructs targeting either BRCA1 or BRCA2 (Figure 1b ; Tutt et al., 2005; McCabe et al., 2006) and clonogenic survival assays were performed. Our results showed that inhibition of Tankyrase 1 was selectively lethal in cells with a reduction in either BRCA1 or BRCA2 expression, but had no effect in control cells (Figure 1c ).
To validate these observations, we used HTC75 human fibrosarcoma cell lines expressing three truncated forms of Tankyrase 1 (ARCV, ARC1 and DANK). We silenced BRCA1 or BRCA2 expression in these cells and compared their survival to cell lines that stably express full-length Tankyrase 1 (TANK-1) or the empty vector (MOCK) (Figure 2a ; Seimiya et al., 2004) .
Loss of the ARCV domain of Tankyrase 1 has previously been shown to reduce significantly the ability of Tankyrase 1 to poly(ADP-ribosyl)ate TRF1 and release TRF1 from telomeres, thereby preventing telomere elongation (Seimiya and Smith, 2002; Seimiya et al., 2004) . Silencing of BRCA1 or BRCA2 significantly increased lethality in the ARCV-expressing cells compared to the isogenic control cell lines MOCK and TANK-1 (Figure 2b ). Interestingly, cells stably expressing other truncated forms of Tankyrase 1, ARC1 and DANK, did not show any selective lethality when transfected with pSUPER-BRCA1 or pSUPER-BRCA2 compared to the control cells. As the ARC1 and DANK cell lines do not show the same TRF1 telomeric release . Whole-cell extracts from HCT116-Control shRNA and HCT116-Tankyrase-1 shRNA cells were prepared as previously described (Seimiya et al., 2004) and were subjected to western blot analysis with indicated antibodies. The reduction in Tankyrase 1 expression in Tankyrase-silenced cells is indicated at the bottom. (b) BRCA1/2 mRNA levels quantified by qPCR following transfection with pSUPER-SCRAMBLED, pSUPER-BRCA1 or pSUPER-BRCA2 constructs. BRCA1/2 expression was calculated relative to the expression of b-actin control, and normalized to the expression in pSUPER-SCRAMBLED transfected cells. (c) Reduced Tankyrase 1 expression is selectively lethal with silencing of BRCA1 and BRCA2. Cell viability graph of HCT116 cells stably expressing either control or Tankyrase-1-specific shRNAs (HCT116-Control shRNA and HCT116-Tankyrase-1 shRNA). Cells were transfected with pSUPER-SCRAMBLED, pSUPER-BRCA1 or pSUPER-BRCA2 constructs, in combination with pEF-Bsd (Invitrogen, Paisley, UK), a construct encoding a blasticidin resistance protein; 24 h after transfection, cells were reseeded in six-well plates and nontransfected cells were removed by blasticidin treatment. After 14-16 days blasticidin exposure, resistant colonies were stained with crystal violet and quantified. Results show the mean of three independent experiments. *Po0.05 and **Po0.01 compared to control cells (Student's t-test).
Targeting Tankyrase 1 in BRCA-deficient cells N McCabe et al defects present in the ARCV cell line (Seimiya et al., 2004) , this result suggests that the mechanism of lethality might be dependent on modifying TRF1 function. TRF1 is a member of the shelterin complex and functions predominantly at the telomeres (de Lange, 2005) . Therefore, we analysed whether the synthetic lethality between Tankyrase 1 and BRCA was due to a cumulative negative impact on telomere maintenance. Loss of functional telomeres results in the appearance of DNA damage foci (known as TIFs or telomeredysfunction-induced foci) and eventually end-to-end fusions (d'Adda di Fagagna et al., 2003) . We monitored the presence of TIFs by immunofluorescence and the frequency of chromosome fusions by fluorescent in situ hybridization in ARCV and MOCK cells transfected with either BRCA-silencing plasmids or the control plasmid. Our results showed that the combined loss of function of Tankyrase 1 and BRCA did not cooperate in inducing telomere dysfunction (data not shown), indicating that the main mechanism of synthetic lethality between Tankyrase 1 and BRCA is unlikely to be dependent on their effects at the telomeres. BRCA mutations are predominantly found in breast and ovarian cancers. To validate our findings we used two human tumor cell lines with known BRCA1 mutations and loss of function, the breast cancer cell line HCC1937 and the ovarian cancer cell line UWB1.289 (DelloRusso et al., 2007) . We silenced Tankyrase 1 expression in these cells by retroviral infection with a vector expressing either a nontargeting shRNA (sh-ctrl) or two shRNA targeting Tankyrase (sh-TNK5 and sh-TNK6; see Supplementary Figure 1S ) and performed clonogenic survival assays in the presence of puromycin selection. As shown in Figure 3 , inhibition of Tankyrase expression in both BRCA1 mutant lines resulted in loss of viability, confirming our previous results.
To further validate this effect, we transfected the breast cancer cell line, CAL51, with combinations of BRCA1 and Tankyrase siRNA (Supplementary Figure  2S) and performed clonogenic survival assays. As shown in Supplementary Figure 2S , knockdown of both BRCA1 and Tankyrase resulted in reduction of cell viability compared to control cells as well as cells transfected with either siRNA alone.
Besides its telomere function, Tankyrase 1 has also been localized to the mitotic spindle poles (Smith and de Lange, 1999) . BRCA1-and BRCA2-deficient cells have also been previously shown to display centrosome amplification and furthermore BRCA1 has been shown to interact with the centrosome in M-phase cells (Tutt Xu et al., 1999) . Therefore, we investigated whether the synthetic lethality between BRCA and Tankyrase 1 was because of the exacerbation of known mitotic phenotypes associated with BRCA deficiency. HTC75 cells expressing the truncated forms of Tankyrase 1 and the isogenic control cell lines, MOCK and TANK-1, were transfected with BRCA1-or BRCA2-silencing plasmids and the number of centrosomes analysed by immunofluorescence. We observed a significant increase in the number of cells with centrosome amplification after silencing of BRCA1 or BRCA2 alone compared to controls, consistent with previous studies (Figures 4a and b ; Tutt et al., 1999; Xu et al., 1999) . However, this phenotype was considerably exacerbated in cells with silenced BRCA1 or BRCA2 in the presence of the ARCV Tankyrase 1 mutant (Figures  4a and b) . This difference was statistically significant (Po0.05) when compared to control cells. A similar phenotype was also observed with HCT116 derivatives. A higher percentage of HTC116-Tankyrase 1 shRNA cells displayed centrosome amplification when transfected with pSUPER-BRCA1 or pSUPER-BRCA2 compared to cells transfected with the control plasmid (Figures 4a and c) . These results suggest that the increased lethality associated with combined loss of BRCA1 or BRCA2 and Tankyrase 1 is characterized by excessive centrosome amplification. As multiple centrosomes are known to result in severe chromosomal missegregation at cell division (Nigg, 2002) , we hypothesize that loss of Tankyrase 1 function in combination with BRCA deficiency leads to excessive centrosome amplification and high levels of chromosomal missegregation that is incompatible with cell viability. Although the mechanisms that control centrosome amplification are unclear, it has previously been proposed that genetic instability and centrosome amplification aberrations enhance each other (Nigg, 2002) . Given the well-documented roles of BRCA1 and BRCA2 in the maintenance of genome stability , it is likely that BRCA deficiency contributes to centrosome amplification by this route. Tankyrase 1 dysfunction had not previously been directly associated with centrosome amplification. However, Tankyrase-1-silenced cells have been demonstrated to accumulate in M phase (Dynek and Smith, 2004) and have abnormal spindle structures . Therefore, it is possible that a combination of genomic instability (caused by BRCA deficiency) and spindle dysfunction (caused by Tankyrase 1 deficiency) causes centrosome amplification and, ultimately, cell death. Regardless of the exact mechanism, the demonstration of synthetic lethality suggests that a therapeutic approach that is based on interfering with Tankyrase 1 function in patients with BRCA-associated tumors is worthy of further investigation. Given that specific, high potency, small-molecule inhibitors of PARP1 and PARP2 proteins have already been developed, it seems likely that similar inhibitors could be developed for Tankyrase 1. Furthermore, it is conceivable that such therapeutics might be exploited to treat not only BRCAassociated cancers but also sporadic cancers displaying properties of 'BRCAness' or those with deficiencies in the HR pathway (Turner et al., 2004) . Figure 1S ). shRNAs were designed and retrovirus was generated as previously described (Silva et al., 2005) . Cells were infected with retroviruses encoding the control shRNA (sh-ctrl) or Tankyrase-1-specific shRNAs (sh-TNK5 and sh-TNK6) and 48 h later seeded in six-well plates and put in selection with puromycin. After 14-16 days colonies were counted and quantified. Results show the mean of three independent experiments. *Po0.05 and **Po0.01 compared to control cells (Student's t-test).
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